Michelle Glass

Has grant

University of Otago

New Zealand

Research Interests

Explore related searches

Professors in New Zealand

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Unlocking the therapeutic potential of the human cannabinoid CB1 receptor: Rational design of novel allosteric modulators.

Open Date: 2023-01-01

Close Date: 2026-01-01

Grant: Close

Applying human drug discovery approaches to kauri die back.

Open Date: 2019-01-01

Close Date: 2022-01-01

Articles (18)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Iain Greig

University of Aberdeen

UNITED KINGDOM

View details

Joel Tyndall

University of Otago

NEW ZEALAND

View details

Daniel F. Legler

Professor for Immunology and Cell Biology

SWITZERLAND

View details

Eric Sparkes

Associate Lecturer (Pharmaceutical Science)

University of Sydney

AUSTRALIA

View details

Natasha Grimsey

University of Auckland

NEW ZEALAND

View details

Jun-Xu Li

Professor

University at Buffalo

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michelle Glass

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (18)

Positive allosteric modulation of the cannabinoid CB1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics

The impact of piperazine and antipsychotic co-exposures and CB1 blockade on the effects elicited by AMB-FUBINACA, a synthetic cannabinoid, in mice

Potential Implications of Multi-Drug Exposure with Synthetic Cannabinoids: A Scoping Review of Human Case Studies

GPCR kinase subtype requirements for arrestin-2 and -3 translocation to the cannabinoid CB1 receptor and the consequences on G protein signalling

Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists

A quantitative pharmacology model for cannabinoid CB1 receptor mediated by Gi/Gs protein competition

Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB1 receptor

A kinetic model for positive allosteric modulator (PAM)‐antagonists for the type 1 cannabinoid (CB1) receptor

Cannabinoid 1 (CB1) receptor arrestin subtype‐selectivity and phosphorylation dependence

Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor

In vitro characterisation of 6-methyl-3-(2-nitro-1-(thiophen- 2-yl)ethyl)-2-phenyl-1Hindole (ZCZ011) at the type 1 cannabinoid receptor

Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β‐arrestins and GPCR kinases

Covalent cannabinoid receptor ligands – structural insight and selectivity challenges

Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies

Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior.

Exploring group size for statistical analysis of real‐time signalling experiments

Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias

Collaborators (6)

Iain Greig

Joel Tyndall

Daniel F. Legler

Eric Sparkes

Natasha Grimsey

Jun-Xu Li

Make your next move.